The Cooper Companies, Inc. presents a balanced investment opportunity in the healthcare sector. With its dual focus on CooperVision and CooperSurgical, it leverages a diverse product portfolio in vision care and women's health. Although the company faces competition and regulatory challenges, its established market presence and innovation in product development are noteworthy.
The fundamental analysis reflects a moderate performance with room for improvement across various financial metrics.
| Category | Score | Visual |
|---|---|---|
| Discounted Cash Flow | 3 | |
| Return on Equity | 3 | |
| Return on Assets | 3 | |
| Debt to Equity | 2 | |
| Price to Earnings | 2 | |
| Price to Book | 3 |
The historical scores provide insight into the company's financial progression and areas in need of focus.
| Date | Overall Score | DCF | ROE | ROA | Debt/Equity | P/E | P/B |
|---|---|---|---|---|---|---|---|
| 2026-02-13 | 3 | 3 | 3 | 3 | 2 | 2 | 3 |
| Previous | 0 | 3 | 3 | 3 | 2 | 2 | 3 |
Analysts provide mixed projections, suggesting caution around market volatility and potential upside within set ranges.
| High | Low | Median | Consensus |
|---|---|---|---|
| $100 | $73 | $96.5 | $91.63 |
The sentiment leans positive, with a majority of analysts recommending a buy.
| Recommendation | Count | Visual |
|---|---|---|
| Strong Buy | 0 | |
| Buy | 15 | |
| Hold | 8 | |
| Sell | 1 | |
| Strong Sell | 0 |
The Cooper Companies, Inc. offers a stable investment opportunity within the healthcare sector with a focus on vision care and women's health. While the company demonstrates moderate financial performance, its ratings suggest potential for improvement. Analyst sentiment remains positive, although investors should consider the potential risks associated with competition and market changes. The stock offers growth potential but requires a balanced approach to portfolio allocation.